Semaglutide vs Survodutide

Semaglutide is a GLP-1 receptor agonist already approved by the FDA to treat type 2 diabetes, obesity, chronic kidney disease, and cardiovascular risk reduction, and is sold under brand names like Ozempic, Wegovy, and Rybelsus. Survodutide, on the other hand, is a dual-acting drug that targets both GLP-1 and glucagon receptors and is still in the pipeline, meaning it has not yet received FDA approval for any use.

AI summary of the sources below.